ImmuCell Free Cash Flow 2010-2024 | ICCC

ImmuCell free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.

ImmuCell Free Cash Flow 2010-2024 | ICCC

ImmuCell free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$204.7B
Stryker (SYK)$141.7B
Boston Scientific (BSX)$123B
Medtronic (MDT)$115.6B
EssilorLuxottica (ESLOY)$106.1B
Haleon (HLN)$48.4B
Lonza Group Ag (LZAGY)$47.3B
ResMed (RMD)$37B
Koninklijke Philips (PHG)$29.1B
Terumo (TRUMY)$27.8B
Zimmer Biomet Holdings (ZBH)$21.9B
Baxter (BAX)$20.5B
Insulet (PODD)$16.4B
Smith & Nephew SNATS (SNN)$13.8B
Bio-Rad Laboratories (BIO)$9.2B
Demant (WILYY)$9.2B
BellRing Brands (BRBR)$7.6B
Lantheus Holdings (LNTH)$7.5B
ICU Medical (ICUI)$4.4B
Haemonetics (HAE)$3.9B
TG Therapeutics (TGTX)$3.9B
Perrigo (PRGO)$3.8B
GN Store Nord (GNNDY)$3.7B
Prestige Consumer Healthcare (PBH)$3.7B
Neogen (NEOG)$3.5B
Envista Holdings (NVST)$3.2B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.3B